Doses - CARBOPLATIN
Note: Do not confuse cisplatin and carboplatin dosages. Cisplatin dosages are much lower than carboplatin dosages.Dogs:
a) As adjunctive treatment of osteogenic sarcoma: 300 mg/meter2 BSA IV every 21 days (Bergman, MacEwen et al. 1996)
b) As adjunctive treatment of osteogenic sarcoma: 300 mg/meter2 BSA IV (admixed with D5W and given IV over 15 minutes) usually within 7 days after amputation. Additional treatments given every 21 days for a total of 4 treatments. (Johnston 1997)
c) As adjunctive treatment of osteogenic sarcoma, melanomas, or various carcinomas:Large Dogs:
350 mg/meter2 BSA IV (diluted in dextrose) every 3 weeks; Small Dogs:
300 mg/meter2 BSA IV (diluted in dextrose) every 3 weeks (London and Frimberger 1997)Cats:
a) As adjunctive treatment of osteogenic sarcoma, melanomas or various carcinomas: 210mg/meter2 BSA IV (diluted in dextrose) every 3 weeks (London and Frimberger 1997)
Monitoring Parameters - 1) CBC; 2) Serum electrolytes, uric acid; 3) Baseline renal and hepaticfunction tests
Client Information - Clients should fully understand the potential toxicity of this agent andideally should give informed consent for its use. As carboplatin (and any platinum containingmetabolites) are principally excreted in the urine over several days after treatment, clients should bewarned to avoid direct contact with patient's urine.
Dosage Forms/Preparations/FDA Approval Status - Veterinary-Approved Products: None
Directions for reconstitution for the 50 mg vial: Add 5 ml of either sterile water forinjection, normal saline injection or D5W that will provide a solution containing 10mg/ml. May infuse directly (usually over 15 minutes) or further dilute. Visually inspectafter reconstitution/dilution for discoloration or particulate matter.
Dogs: 
a) As adjunctive treatment of osteogenic sarcoma: 300 mg/meter2 BSA IV every 21 days (Bergman, MacEwen et al. 1996) b) As adjunctive treatment of osteogenic sarcoma: 300 mg/meter2 BSA IV (admixed with D5W and given IV over 15 minutes) usually within 7 days after amputation. Additional treatments given every 21 days for a total of 4 treatments. (Johnston 1997)
c) As adjunctive treatment of osteogenic sarcoma, melanomas, or various carcinomas:
Large Dogs:
350 mg/meter2 BSA IV (diluted in dextrose) every 3 weeks; Small Dogs:
300 mg/meter2 BSA IV (diluted in dextrose) every 3 weeks (London and Frimberger 1997)Cats: 
a) As adjunctive treatment of osteogenic sarcoma, melanomas or various carcinomas: 210mg/meter2 BSA IV (diluted in dextrose) every 3 weeks (London and Frimberger 1997) Monitoring Parameters - 1) CBC; 2) Serum electrolytes, uric acid; 3) Baseline renal and hepaticfunction tests
Client Information - Clients should fully understand the potential toxicity of this agent andideally should give informed consent for its use. As carboplatin (and any platinum containingmetabolites) are principally excreted in the urine over several days after treatment, clients should bewarned to avoid direct contact with patient's urine.
Dosage Forms/Preparations/FDA Approval Status - Veterinary-Approved Products: None
Human-Approved Products:
Carboplatin Powder for reconstitution and IV Injection 50 mg, 150 mg, & 450 mg vials(contains mannitol); Paraplatin® (Bristol-Myers Squibb); (Rx)Directions for reconstitution for the 50 mg vial: Add 5 ml of either sterile water forinjection, normal saline injection or D5W that will provide a solution containing 10mg/ml. May infuse directly (usually over 15 minutes) or further dilute. Visually inspectafter reconstitution/dilution for discoloration or particulate matter.